Extended Data Fig. 9: Proof-of-concept treatments were tested on patient fibroblasts and Pfa1 cells, which were knocked out of endogenous GPX4 and transfected to overexpress human mScarlet-tagged GPX4WT (red) or GPX4R152H (blue).
From: Characterization of a patient-derived variant of GPX4 for precision therapy
a-b, Supplementations of methyl-seleno-cysteine and N-acetyl-cysteine were tested as proof-of-concept treatments on the patient and control fibroblasts. Data are plotted as means ± SD (n = 3 biologically independent samples). c, Viability was normalized to the corresponding DMSO control. Data are plotted as means ± SD (n = 3 biologically independent samples). See Supplementary Note for effects of α-tocopherol.
